157 related articles for article (PubMed ID: 19951530)
41. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
42. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
43. A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.
Hossain NM; Jain N; Steinmetz JL; McConville JF; Anastasi J; Odenike O
Chest; 2012 Dec; 142(6):1680-1683. PubMed ID: 23208343
[No Abstract] [Full Text] [Related]
44. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
45. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
[TBL] [Abstract][Full Text] [Related]
46. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract][Full Text] [Related]
47. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
Jain N; Khoury JD; Pemmaraju N; Kollipara P; Kantarjian H; Verstovsek S
Blood; 2013 Nov; 122(19):3387-8. PubMed ID: 24203930
[No Abstract] [Full Text] [Related]
48. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
Helbig G; Moskwa A; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Zdziarska B; Brzeźniakiewicz K; Pogrzeba J; Krzemień S
Br J Haematol; 2009 Apr; 145(1):132-4. PubMed ID: 19120352
[No Abstract] [Full Text] [Related]
49. A case of myeloid neoplasm with FIP1L1-PDGFRA rearrangement without marked peripheral blood eosinophilia.
Wang J; Zhang Q; Zeng H; Chen B; Ouyang J
Pharmacogenomics; 2016; 17(2):99-102. PubMed ID: 26666578
[TBL] [Abstract][Full Text] [Related]
50. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
51. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Tsimberidou AM; Colburn DE; Welch MA; Cortes JE; Verstovsek S; O'Brien SM; Albitar M; Kantarjian HM; Giles FJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):229-34. PubMed ID: 12783207
[TBL] [Abstract][Full Text] [Related]
52. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
Shah S; Loghavi S; Garcia-Manero G; Khoury JD
J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
[TBL] [Abstract][Full Text] [Related]
53. [FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy].
Nemchenko IS; Turkina AG; Chelysheva EY; Galstyan GM; Kovrigina AM; Khuazheva NK; Savchenko VG
Ter Arkh; 2015; 87(12):89-95. PubMed ID: 26978425
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate.
Iyama S; Matsunaga T; Sato T; Murase K; Araki N; Takimoto R; Kobune M; Sagawa T; Takayama T; Niitsu Y
Intern Med; 2008; 47(8):791-4. PubMed ID: 18421200
[TBL] [Abstract][Full Text] [Related]
55. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
56. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
57. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate.
Sun CY; Hu Y; Chu ZB; Guo T; He J
Int J Hematol; 2009 Jan; 89(1):66-70. PubMed ID: 19096755
[TBL] [Abstract][Full Text] [Related]
58. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
59. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Srinivasan A; Scordino T; Baker A
J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
[No Abstract] [Full Text] [Related]
60. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]